Beta-blocker therapy stands as a cornerstone in the realm of cardiovascular medicine, offering a multifaceted approach to address various conditions. These pharmacological agents, commonly known as beta-blockers, exert their therapeutic effects by antagonizing the impact of adrenaline, resulting in a reduction of heart rate and blood pressure. Widely prescribed to manage hypertension, angina, and specific cardiac arrhythmias, beta-blockers showcase their effectiveness in diverse cardiovascular scenarios. Notably, their role extends to the management of heart failure, where they contribute to enhancing cardiac function and alleviating symptoms. Post-myocardial infarction care also heavily relies on beta-blocker therapy to prevent subsequent cardiovascular events. Beyond cardiovascular applications, these agents demonstrate versatility, occasionally finding use in mitigating symptoms associated with anxiety and migraine headaches. While generally well-tolerated, the individualized consideration of medical histories and potential contraindications is imperative in the prescription of beta-blocker therapy. A collaborative approach between healthcare providers and patients remains paramount to ensuring optimal cardiovascular health management.
Title : Investigating the long-term follow up of atrial septal device closures in wales and england: A comparative analysis with major adverse cardiovascular Events (MACE)
Meera Gopinath, Cardiff University Medical school, United Kingdom
Title : An adult case of polysplenia syndrome associated with sinus node dysfunction
Apoorva Tripathi, Oxford University Hospitals, United Kingdom
Title : A unique cell-driven phenomenon in the heart and the promising future of the innovative translational tools to manage cardiac self-renewal and regeneration
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Yasser’s criterion of inferior ST-segment discrepancy deviations in AF with aberrancy and Sgarbosa criteria - a new cardiovascular discovery and management - a case report
Yasser Mohammed Hassanain Elsayed, Egyptian Ministry of Health, Egypt